Eginitio Hospital

Running trials

• Recruiting

  A Study to Evaluate The Long-Term Safety And Efficacy of Rozanolixizumab in Adult Participants With Ocular Myasthenia Gravis

  NCT07465289· Phase 3· Source

• Recruiting

  ADAPT Forward 2 - ISA2 - a Study to Evaluate the Safety, Tolerability and Efficacy of Empasiprubart IV Monotherapy in Participants With AChR-Ab Seropositive Generalized Myasthenia Gravis

  NCT07673627· Phase 2· Source

• Recruiting

  A Study to Evaluate the Efficacy and Safety of Rozanolixizumab in Adult Participants With Ocular Myasthenia Gravis

  NCT07463521· Phase 3· Source

• Recruiting

  A clinical trial to find out how well LOU064 (remibrutinib) works and how safe it is for people with secondary progressive multiple sclerosis

  2025-521546-23-00· Phase 3· Source

• Recruiting

  A Study to Investigate the Efficacy, Safety and Tolerability of Votoplam in Participants With Huntington's Disease

  NCT07326709· Phase 3· Source

• Recruiting

  A Study of Orelabrutinib in Patients With Secondary Progressive Multiple Sclerosis

  NCT07299019· Phase 3· Source

• Recruiting

  A Study of Orelabrutinib in Patients With Primary Progressive Multiple Sclerosis

  NCT07067463· Phase 3· Source

• Recruiting

  A Study to Test if Tenecteplase Helps People to Recover From an Acute Stroke When Given More Than 4.5 Hours After the Person Was Last Seen Well

  NCT07361302· Phase 3· Source

• Recruiting

  ADAPT Forward - Master Protocol of a Platform Study to Evaluate the Safety and Efficacy of Multiple Regimens in Participants With Myasthenia Gravis

  NCT07294170· Source

• Recruiting

  ADAPT Forward 1 - ISA1 - a Study to Evaluate Empasiprubart IV as add-on Therapy to Efgartigimod IV in Participants With AChR-Ab Seropositive Generalized Myasthenia Gravis With a Partial Clinical Response to Efgartigimod

  NCT07284420· Phase 2· Source

• Recruiting

  A Study to Evaluate the Long-term Efficacy and Safety of KarXT + KarX-EC for Agitation in Alzheimer's Disease (ADAGIO-3)

  NCT06937229· Phase 3· Source

• Recruiting

  A Study to Assess the Efficacy and Safety of Empasiprubart in Adults With CIDP

  NCT07091630· Phase 3· Source

• Enrolling by invitation

  Phase III Long-term Extension Trial to Assess Safety and Efficacy of CYB003 in MDD (EXTEND)

  NCT06605105· Phase 3· Source

• Recruiting

  A Study to Evaluate the Efficacy and Safety of KarXT + KarX-EC for Cognitive Impairment in Alzheimer's Disease

  NCT06976216· Phase 3· Source

• Recruiting

  A Phase 3 Study to Evaluate the Safety and Efficacy of KarXT + KarX-EC for the Treatment of Agitation Associated With Alzheimer's Disease (ADAGIO-1)

  NCT07011732· Phase 3· Source

• Recruiting

  Study to Assess the Efficacy and Safety of IMVT-1402 in Participants With Mild to Severe Generalized Myasthenia Gravis

  NCT07039916· Phase 3· Source

• Recruiting

  Imeroprubart in Adult Participants With Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)

  NCT07032662· Phase 2· Source

• Recruiting

  The Effect of a Six Week Intensified Pharmacological Treatment for Bipolar Depression Compared to Treatment as Usual in Subjects Who Had a First-time Treatment Failure on Their First-line Treatment.

  NCT05973786· Phase 3· Source

• Active, not recruiting

  A Study to Assess Efficacy and Safety of Efgartigimod PH20 SC in Adults With Ocular Myasthenia Gravis

  NCT06558279· Phase 3· Source

• Recruiting

  The Effect of a Six Week Intensified Pharmacological Treatment for Major Depressive Disorder Compared to Treatment as Usual in Subjects Who Had a First-time Treatment Failure on Their First-line Treatment.

  NCT05973851· Phase 3· Source

• Active, not recruiting

  A Phase III Study to Investigate Efficacy, Safety and Tolerability of Iptacopan Compared With Placebo in Participants Aged 18 to 85 Years With gMG.

  NCT06517758· Phase 3· Source

• Active, not recruiting

  A Phase 3 Study to Evaluate the Efficacy and Safety of Efgartigimod IV in Patients With Acetylcholine Receptor Binding Antibody Seronegative Generalized Myasthenia Gravis

  NCT06298552· Phase 3· Source

• Active, not recruiting

  A Study to Evaluate the Effect of Venglustat Tablets on Neuropathic and Abdominal Pain in Male and Female Participants ≥16 Years of Age With Fabry Disease

  NCT05206773· Phase 3· Source

• Active, not recruiting

  Efficacy and Safety of Remibrutinib Compared to Teriflunomide in Participants With Relapsing Multiple Sclerosis (RMS) (REMODEL-2)

  NCT05156281· Phase 3· Source

• Active, not recruiting

  Study to Evaluate the Efficacy and Safety of Fenebrutinib Compared With Teriflunomide in Relapsing Multiple Sclerosis (RMS)

  NCT04586023· Phase 3· Source

• Active, not recruiting

  A Study to Evaluate the Efficacy and Safety of Fenebrutinib Compared With Ocrelizumab in Adult Participants With Primary Progressive Multiple Sclerosis

  NCT04544449· Phase 3· Source

Recruiting at the same time

How many trials recruit for the same indication here at once. A count, not a rating.

• Myasthenia gravis6 recruiting
• Alzheimer disease3 recruiting
• Multiple sclerosis3 recruiting
• CIDP (chronic inflammatory demyelinating polyneuropathy)2 recruiting
• Depression2 recruiting
• Bipolar disorder1 recruiting
• Huntington's disease1 recruiting
• Stroke1 recruiting

Researchers

No researcher is linked here yet.

Closed trials

• Completed

  A Randomized, Double-blind, Multicenter, Placebo-controlled Study of Adjunctive Aticaprant Plus an Antidepressant for Relapse Prevention in Major Depressive Disorder (MDD) With Moderate-to-severe Anhedonia

  2024-511057-22-00· Phase 3· Source

• Completed

  A 96-Week, Prospective, Multicenter, Randomised, Double-Blind, Placebo-Controlled, Phase 3 Study to Compare Efficacy and Safety of Masitinib Dose Titration to 4.5 mg/kg/day versus Placebo in the Treatment of Patients with Primary Progressive or Secondary Progressive Multiple Sclerosis Without Relapse

  2024-516672-16-00· Phase 3· Source

• Completed

  Phase 2b Study to Assess Efficacy and Safety of Batoclimab in Adult Participants with Active CIDP.

  2024-512646-42-00· Phase 2· Source

• Completed

  A Study to Test Asundexian for Preventing a Stroke Caused by a Clot in Participants After an Acute Ischemic Stroke or After a High-risk Transient Ischemic Attack, a So-called Mini Stroke

  NCT05686070· Phase 3· Source

• Completed

  A study to test long-term safety of Iclepertin in people with schizophrenia who took part in a previous CONNEX study

  2024-511560-93-00· Phase 3· Source

• Completed

  A Research Study Investigating Semaglutide in People With Early Alzheimer's Disease (EVOKE)

  NCT04777396· Phase 3· Source

• Completed

  A Research Study Investigating Semaglutide in People With Early Alzheimer's Disease (EVOKE Plus)

  NCT04777409· Phase 3· Source

• Completed

  Assessment of the Efficacy, Safety, and Tolerability of AVP-786 for the Treatment of Agitation in Patients With Dementia of the Alzheimer's Type

  NCT04408755· Phase 3· Source

• Active, not recruiting

  A Study to Evaluate the Efficacy, Safety and Pharmacokinetics (PK) of a Higher Dose of Ocrelizumab in Adults With Primary Progressive Multiple Sclerosis (PPMS)

  NCT04548999· Phase 3· Source

• Completed

  Primary Progressive Multiple Sclerosis (PPMS) Study of Bruton's Tyrosine Kinase (BTK) Inhibitor Tolebrutinib (SAR442168) (PERSEUS)

  NCT04458051· Phase 3· Source

• Completed

  A Phase 3 Study to Evaluate Efficacy and Safety of AL001 in Frontotemporal Dementia (INFRONT-3)

  NCT04374136· Phase 3· Source

• Completed

  A Study to Assess the Long-term Safety and Efficacy of ATB200/AT2221 in Adult Subjects With Late-Onset Pompe Disease (LOPD)

  NCT04138277· Phase 3· Source